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Abstract: Perioperative hypertension is commonly encountered in patients that undergo 
surgery. While attempts have been made to standardize the method to characterize the 
intraoperative hemodynamics, these methods still vary widely. In addition, there is a lack of 
consensus concerning treatment thresholds and appropriate therapeutic targets, making absolute 
recommendations about treatment difﬁ  cult. Nevertheless, perioperative hypertension requires 
careful management. When treatment is necessary, therapy should be individualized for the patient. 
This paper reviews the pharmacologic agents and strategies commonly used in the management 
of perioperative hypertension.
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Introduction
In the United States, it is that estimated approximately 72 million people suffer 
hypertension (Rosamond et al 2007). Affecting ~30% of the US population 20 
years-old, hypertension is one of the most common chronic medical conditions (Hajjar 
and Kotchen 2003; US National Center for Health Statistics 2005), and occurs almost 
twice as often in African-Americans as opposed to Caucasians (Burt et al 1995a, 
1995b; Kearse et al 1998). Moreover, the incidence of hypertension increases with 
age (Dannenberg et al 1988; Borzecki et al 2003) and affects men at a slightly higher 
rate than women. Worldwide, hypertension may affect as many as 1 billion people 
and be responsible for ~7.1 million deaths per year (WHO 2002). Considering the 
prevalence of chronic hypertension, the management of patients with chronic hyper-
tension undergoing surgery is of major clinical importance as these patients are at an 
increased risk of morbidity and mortality after surgery.
Hypertension is a frequent complication of cardiac surgery (Estafanous et al 
1973; Viljoen et al 1976; Estafanous and Tarazi 1980). Perioperative hypertension 
occurs in 25% of hypertensive patients that undergo surgery (Prys-Roberts et al 1971; 
Goldman and Caldera 1979). During surgery, patients with and without preexisting 
hypertension are likely to develop blood pressure elevations and tachycardia during 
the induction of anesthesia (Erstad and Barletta 2000). Common predictors of peri-
operative hypertension are previous history of hypertension, especially a diastolic 
blood pressure greater than 110 mm Hg, and the type of surgery (Khuri et al 1995; 
Aronson et al 2002, 2007).
The Sixth Report of the Joint National Committee on Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC6) (Chobanian et al 2003a; JNC 1997) identi-
ﬁ  es patients with a systolic blood pressure (BP) of 180 mm Hg, or a diastolic that is 
110 mm Hg, as having a “hypertensive crisis”. Hypertensive crisis is a term referring 
to either hypertensive emergencies or urgencies.
Hypertensive emergencies (ie, severe elevations in BP [180/110 mm Hg] compli-
cated by evidence of impending or progressive target organ dysfunction) require imme-
diate BP reduction to prevent or limit end organ damage. Examples of hypertensive Vascular Health and Risk Management 2008:4(3) 616
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emergencies include hypertensive encephalopathy, intra-
cerebral hemorrhage, subarachnoid hemorrhage, and acute 
stroke; hypertension-induced acute renal dysfunction; and 
hypertension associated with unstable angina, acute myocar-
dial infarction, acute coronary heart failure, and acute aortic 
dissection. Blood pressure should be reduced by 10%–15% 
(maximum of 20%) in a controlled fashion within the ﬁ  rst 
hour with a continued decrease towards 160/100 mm Hg over 
the next 2–6 hours as tolerated by the patient. A more rapid 
reduction is indicated in patients with aortic dissection.
Hypertensive urgencies are those situations associated 
with severe elevations in BP without progressive target 
organ dysfunction. Since end organ dysfunction is not pres-
ent, hypertensive urgencies require less rapid reductions in 
pressure (ie, hours to days).
This article reviews the treatment options available for 
the management of hypertension in patients undergoing 
surgery. Due to the low incidence of hypertension in the 
pediatric population, this review is limited to the manage-
ment of perioperative hypertension in adult patients. In this 
article, the term perioperative refers to the time of hospital-
ization directly related to a surgical procedure; and includes 
the preoperative, intraoperative, and postoperative (ie, 3 or 
4 days post) periods.
Incidence
Perioperative hypertension often occurs in conjunction with 
one of the following events: during the induction of anesthe-
sia; intraoperatively as associated with acute pain-induced 
sympathetic stimulation leading to vasoconstriction; in the 
early postanesthesia period, associated with pain induced 
sympathetic stimulation, hypothermia, hypoxia, or intravas-
cular volume overload from excessive intraoperative ﬂ  uid 
therapy; and in the 24 to 48 hours after postoperatively as ﬂ  uid 
is mobilized from the extravascular space. In addition, blood 
pressure elevation secondary to discontinuation of long-term 
antihypertensive medication may occur postoperatively.
Hypertensive events occur most commonly with carotid 
surgery, abdominal aortic surgery, peripheral vascular proce-
dures, and intraperitoneal, or intrathoracic, surgery (Goldman 
and Caldera 1979). At least 25% of patients undergoing 
noncardiac surgery have hypertension prior to their surgi-
cal procedure; elevated blood pressures (eg, systolic 170 
mm Hg, diastolic 110 mm Hg) have been associated with 
complications such as myocardial ischemia (Goldman et al 
1977, 1997).
Data suggest that diastolic blood pressure of 110 mm Hg is 
a preoperative marker of perioperative cardiac complications in 
patients with chronic hypertension (Goldman et al 1977). 
Patients with uncontrolled hypertension (ie, 170/95 mm Hg) 
undergoing carotid endarterectomies have been shown to 
have a signiﬁ  cantly greater number of postoperative neuro-
logic deﬁ  cits (p  0.01) than patients with better control or 
normotensive patients (Towne and Bernhard 1980; Asiddao 
et al 1982). Therefore, patients on antihypertensive therapy 
should maintain compliance to their treatment regimen prior to 
surgery, including the morning of surgery, as it may contribute 
to fewer intraoperative blood pressure ﬂ  uctuations (Goldberg 
and Larijani 1998; Chobanian et al 2003a).
Preoperative hypertension
Preoperative hypertension is frequently a hypertensive 
urgency, not an emergency, as it typically does not involve 
end organ damage and there usually adequate time to reduce 
the BP (Goldberg and Larijani 1998). A prospective, random-
ized multicenter study of more than 17,000 patients found that 
preoperative hypertension was associated with perioperative 
bradycardia, tachycardia, and hypertension (Forrest et al 
1992). In a multivariate analysis of risk factors for periop-
erative complications in men who underwent noncardiac 
surgery, the presence of preoperative hypertension increased 
the odds ratio for postoperative death to 3.8 times that of nor-
motensives (Browner et al 1992). In a case-controlled study 
of patients who died of a cardiac cause within 30 days of 
elective surgery, a preoperative history of hypertension was 
4 times more likely than in an equal number of age-matched 
controls (Howell et al 1996).
Overall, the incidence of substantial intraoperative BP 
elevations (ie, systolic pressure 160 mm Hg) in hyperten-
sive patients undergoing noncardiac elective surgery appears 
to be 10% with appropriate patient selection (ie, controlled 
hypertension) (Mangano et al 1990). Patients with higher 
preoperative BP undergoing elective surgery are at risk for 
increased perioperative hypertensive episodes, though the 
relationship of these episodes to clinically important com-
plications has not been clearly demonstrated. Nonetheless, 
postponement of elective surgery is usually recommended 
until the BP is adequately controlled (Wolfsthal 1993). In 
patients with chronic hypertension, as long as the diastolic 
BP is 110 mm Hg, it is not considered a reason to delay 
surgery.
When emergent surgery is necessary, excessive BP 
elevations should be lowered to limit or prevent possible 
aggravation of bleeding and damage to vital organs. Assum-
ing there is no immediate threat to vital organ function, as 
may occur in patients with end organ disease secondary to Vascular Health and Risk Management 2008:4(3) 617
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chronic hypertension, such perioperative elevations in BP 
can generally be considered hypertensive urgencies (Mann 
and Atlas 1995).
Characterized by excessive sympathetic activity 
with rebound hypertension, clonidine withdrawal 
syndrome often resembles the hypertensive crisis of 
pheochromocytoma and may be misdiagnosed (Houston 
1981; O’Connor 1981; Berge and Lanier 1991; Neusy and 
Lowenstein 1989). Symptoms of clonidine withdrawal 
syndrome are typically encountered 18 to 24 hours after 
sudden discontinuation of clonidine in patients taking more 
than 1.0 mg/day. The simultaneous use of a nonselective 
beta-blocker may exacerbate clonidine withdrawal 
syndrome. Because there is no rapidly acting, parenteral 
form of this drug for use in patients who are unable to 
take oral medication, clonidine withdrawal syndrome is of 
particular concern in the perioperative period. Clonidine 
withdrawal syndrome may be corrected by reintroducing 
clonidine, either intramuscularly, or through treatment with 
methyldopa and labetalol. Preoperatively, the clonidine 
withdrawal syndrome can be prevented by converting the 
patient to a clonidine patch.
Intraoperative and postoperative 
hypertension
Acute elevations in blood pressure (20%) in the 
intraoperative period are typically considered hypertensive 
emergencies (Goldberg and Larijani 1998). Postoperative 
hypertension (arbitrarily deﬁ  ned as systolic BP 190 mm Hg 
and/or diastolic BP 100 mm Hg on 2 consecutive readings 
following surgery) (Plets 1989; Chobanian et al 2003b) 
may have signiﬁ  cant adverse sequelae in both cardiac and 
noncardiac patients. Hypertension, and hypertensive crises, 
are very common in the early postoperative period and are 
related to increased sympathetic tone and vascular resistance 
(Roberts et al 1977; Alper and Calhoun 2002). Postoperative 
hypertension often begins ~10–20 minutes after surgery 
and may last up to 4 hours (Towne and Bernhard 1980). 
If left untreated, patients are at increased risk for bleeding, 
cerebrovascular events, and myocardial infarctions (Goldberg 
and Larijani 1998).
In the surgical setting, acute severe hypertension may be 
encountered during cardiac surgery, major vascular surgery 
(eg, carotid endarterectomy, aortic surgery), neurosurgery, 
head and neck surgery, renal transplantation, and major 
trauma (ie, burns or head injury). The incidence of postopera-
tive hypertensive crises varies depending on the population 
examined, being reported in 4 to 35% of patients shortly 
after the surgical procedure (Gal and Cooperman 1975; 
Prys-Rroberts 1984; Halpern et al 1990).
Patients with a personal or family history of cerebral 
hemorrhage are an example of a population at particular 
risk for complications related to these abrupt increases in 
blood pressure (Frohlich 1998). In addition, certain types of 
surgery (eg, coronary artery bypass surgery, aortic aneurysm 
repair, carotid endarterectomy) are associated with high rates 
of postoperative hypertension (McKillion and Dellinger 
1997). Like other forms of hypertensive crises, a history 
of hypertension is commonly seen in patients with periop-
erative hypertension. The transient nature of postoperative 
hypertension, and the unique clinical factors present in the 
postoperative period, requires that this clinical syndrome be 
given particular attention.
Treatment
The approach to the treatment of perioperative hyperten-
sion is considerably different than the treatment of chronic 
hypertension (Levy 1993). The initial approach to treatment 
is prevention. Because many patients that develop postop-
erative hypertension do so as a result of withdrawal of their 
long-term antihypertensive regimen, this withdrawal should 
be minimized in the postoperative period. One preventive 
approach is to substitute long-acting preparations of the 
patient’s long-term antihypertensive regimen starting, if 
possible, several days before surgery and to be given in the 
morning of the day of surgery.
In all cases, the possible causes of the patient’s BP eleva-
tion should be considered, and it should be decided if the 
hypertension is a hypertensive emergency or urgency. In 
patients with a hypertensive emergency, it usually is neces-
sary to treat with a parenteral antihypertensive agent. In the 
acute setting, the treatment goal is to decrease blood pressure 
by no more than 25% (Chobanian et al 2003a). Advancing 
these guidelines, the authors believe the immediate goal of 
therapy in hypertensive emergencies to reduce diastolic BP 
by 10% to 15%, or to approximately 110 mm Hg, over a 
period of 30 to 60 minutes. Sodium and volume depletion can 
be signiﬁ  cant, and gentle volume expansion with IV saline 
solution will serve to restore organ perfusion and prevent 
an abrupt decline in BP when antihypertensive regimens are 
initiated. This goal decreases the likelihood of too-aggressive 
control, which may result in target organ hypoperfusion. 
Patients with chronic hypertension have cerebral and renal 
perfusion autoregulation shifted to a higher range. The brain 
and kidneys are particularly prone to hypoperfusion if blood 
pressure is lowered too rapidly. With the threat of organ Vascular Health and Risk Management 2008:4(3) 618
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injury diminished, attempts should be made to control blood 
pressure to baseline levels during 24 to 48 hours.
Postoperative hypertensive emergencies are uncommon 
after noncardiac surgery. Hypertension that occurs in relation 
to tracheal intubation, surgical incision, and emergence from 
anesthesia may be treated with short-acting β-blockers, 
angiotensin-converting enzyme (ACE) inhibitors, calcium 
channel blockers, or vasodilators (Weiss and Longnecker 
1993). Postoperative situations that may result in a hypertensive 
emergency include rebound hypertension after withdrawal 
of antihypertensive medications, hypertension resulting in 
bleeding from vascular surgery suture lines, hypertension 
associated with head trauma, and hypertension caused by 
acute catecholamine excess (eg, pheochromocytoma). An 
initial approach is to reverse precipitating factors (pain, 
hypervolemia, hypoxia, hypercarbia, and hypothermia).
Pharmacotherapy
Pharmacotherapy for hypertensive crisis involves a wide 
variety of agents with different mechanisms of action and 
pharmacologic properties. The agent of choice in any par-
ticular situation will depend on the clinical presentation. 
The ideal agent for treatment of hypertensive emergencies 
should be rapid acting, predictable and easily titrated, safe, 
inexpensive, and convenient. Currently, many options are 
available (Table 1), each with distinct advantages and 
disadvantages. Preferred agents include labetalol, esmolol, 
nicardipine, and fenoldopam. Since an immediate reduc-
tion in blood pressure is desired, parenteral agents are dis-
cussed, with emphasis placed on newer agents. Clonidine 
and ACE inhibitors are long acting and poorly titratable; 
however, these agents may be useful in the management of 
hypertensive urgencies. ACE inhibitors are contraindicated 
in pregnancy (DiPette et al 1985; Hirschl et al 1997). A 
review of agents used in the management of perioperative 
hypertension, preferred conditions, and dosing is presented 
in Table 2.
Enalaprilat
Enalaprilat, an ACE inhibitor available for intravenous (IV) 
administration has been studied extensively in the periopera-
tive setting (Yates and Hunter 1988; Acampora et al 1989; 
Murphy et al 1989; Colson et al 1990; Boldt et al 1995; 
Heropoulos et al 1995; Tohmo and Karanko 1995). ACE 
inhibitors have shown efﬁ  cacy in treating hypertension asso-
ciated with congestive heart failure, essential hypertension, 
and prevention of worsening renal function in patients with 
diabetic, and nondiabetic, nephropathy. Enalaprilat has also 
been used preventatively in patients undergoing craniotomy 
(Kross et al 2000).
Table 1 Initial dosing of antihypertensive agentsa
Agent Comment
Enalaprilat Intravenous intermittent: 0.625–1.25 mg (lower dose if hyponatremia, possible volume depletion, concomitant diuretic 
therapy, or renal failure) over 5 min, then double at 4- to 6-h intervals until desired response, a single maximal dose 
of 1.25–5 mg (doses 1.25 mg have not been of additional beneﬁ  t, but doses 5 mg have been given), toxicity, or a 
cumulative dose of 20 mg within a 24-h period; contraindicated in 2nd and 3rd trimester of pregnancy
Esmolol Intravenous infusion: 250–500 µg/kg/min for 1 min, followed by a 50–100 µg/kg/min infusion for 4 min, then titrate 
using same sequence (ie, with bolus before each rate increase) until desired response, a maximal dose of 300 µg/kg/
min, or toxicity
Fenoldopam Intravenous intermittent: 0.1 µg/kg/min initially, then titrate in 0.1 µg/kg/min increments every 15 min until desired 
response, a maximal dose of 1.6 µg/kg/min, or toxicity
Hydralazine Intravenous intermittent: 3–20 mg (the lower end of the dosing range is preferred in the immediate perioperative 
period and in patients with renal failure) slow IV push every 20–60 min
Labetalol Intravenous intermittent: 20 mg over 2 min, then double at 10 min intervals until desired response, a single maximal 
dose of 80 mg, toxicity, or a cumulative dose of 300 mg/d Intravenous infusion: 2 mg/min initially, then titrate in 2 mg 
increments every 10 min until response, toxicity, or a cumulative dose of 300 mg/24-h
Nicardipine Intravenous infusion: 5 mg/h initially, then titrate dose by 2.5 mg/h increments every 5–15 min until desired response, 
a maximal dose of 15 mg/h, or toxicity
Nitroglycerin Intravenous infusion: 5 µg/min initially, then titrate in 5 µg/min increments (may use 10 to 20 µg/min increments 
when doses 20 µg/min) every 3–5 min until desired response or toxicity; no absolute dosing limit, but the risk of 
hypotension increases with doses 200 µg/min; therefore, alternative therapy should be considered
Nitroprusside Intravenous infusion: 0.25–0.5 µg/kg/min initially, then titrate dose every 1–2 min until desired response, a maximal 
dose of 10 µg/kg/min (limit to duration 10 min), or toxicity
Notes: aUse oral dosing when gastrointestinal absorption is documented and when an early response (eg, 2 h) is not needed; the IV dose titration times are the shortest 
times recommended for BP control but not necessarily the best for a given patient; slower titrations are often warranted to preclude excessively rapid decreases in pres-
sure, with subsequent perfusion complications.Vascular Health and Risk Management 2008:4(3) 619
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In general, enalaprilat is administered as an IV injection 
of 1.25 mg over 5 minutes every 6 hours, titrated by incre-
ments of 1.25 mg at 12- to 24-hour intervals up to a maximum 
of 5 mg every 6 hours. Enalaprilat is effective in reducing 
the hypertensive response to endotracheal intubation during 
induction of anesthesia, but caution should be used when 
enalaprilat is used in conjunction with anesthetic agents 
(Hirschl et al 1995).
While the advantages of enalaprilat include bolus dosing 
versus continuous infusion, a lack of reﬂ  ex tachycardia, and 
no effects on intracranial pressure (Schmidt et al 1990; Boldt 
et al 1995), a disadvantage is the delayed onset of action 
(15 minutes). In addition, enalaprilat does not reach peak 
effect for ~1 hour, and its duration of action is ~6 hours. The 
effective half-life for accumulation of enalaprilat is approxi-
mately 11 hours (Merck and Co. 2000). The relatively slow 
onset and long duration of action make enalaprilat a poor 
choice for use in a hypertensive emergency.
In addition, ACE inhibitors have the potential to cause 
acute renal failure, acute renal dysfunction, or hyperkalemia 
in patients in circulatory decompensated states or when mean 
arterial pressure is insufﬁ  cient to support renal perfusion. 
Since surgical patients are at an increased risk for circulatory 
decompensation in the post operative period, ACE inhibitors 
should not be considered ﬁ  rst-line agents in the treatment of 
acute perioperative hypertension.
Esmolol
Esmolol is an ultra-short-acting cardioselective, β-adrenergic 
blocking agent (Lowenthal et al 1985; Reynolds et al 
1986; Gray 1988). Esmolol has been used successfully for 
hypertension in the perioperative period (Cucchiara et al 1986; 
Girard et al 1986; Newsome et al 1986; Gray et al 1987; Gibson 
et al 1988). The metabolism of esmolol is via rapid hydrolysis 
of ester linkages by red blood cell (RBC) esterases and is not 
dependant on renal or hepatic function. Esmolol is especially 
useful in severe postoperative hypertension (Gray et al 1985, 
1987; Stumpf 1988; Platia et al 1989; Muzzi et al 1990; 
Smerling and Gersony 1990; Balser et al 1998) and is an ideal 
choice when cardiac output, heart rate, and BP are increased.
Esmolol has no direct vasodilatory actions. It decreases atrial 
pressure by decreasing heart rate and myocardial contractility 
and thus cardiac output. In general, the drug is administered as 
a 500–1000 µg/kg loading dose over 1 minute, followed by an 
infusion starting at 50 µg/kg/min and increasing up to 300 µg/
kg/min as necessary. Esmolol has a rapid onset (60 seconds) 
and short duration of action (10 to 20 minutes) (Lowenthal et al 
1985; Reynolds et al 1986; Gray 1988). However, the need for 
Table 2   Agents used in the management of perioperative hypertension, preferred conditions, and dosing
Agent Conditions Dosing
Enalaprilat Congestive heart failure IV injection of 1.25 mg over 5 min every 6 h, titrated by increments of 
1.25 mg at 12 to 24 h intervals to a maximum of 5 mg every 6 h.
Esmolol Acute myocardial ischemiaa Loading dose of 500–1000 µg/kg over 1 min, followed by an 
infusion at 25 to 50 µg/kg/min, which may be increased by 
25 µg/kg/min every 10 to 20 min until the desired response to 
a maximum of 300 µg/kg/min
Fenoldopam Acute myocardial ischemiac
Acute pulmonary edema/diastolic dysfunctiona,b
Acute ischemic stroke/intracerebral bleed Acute renal failure/
microangiopathic anemia
Hypertensive encephalopathy
Sympathetic crisis
An initial dose of 0.1 µg/kg/min, titrated by increments of 0.05 
to 0.1 µg/kg/min to a maximum of 1.6 µg/kg/min.
Labetalol Acute aortic dissection
Acute myocardial ischemiaa
Acute ischemic stroke/intracerebral bleed
Eclampsia/Preeclampsia Hypertensive encephalopathy
Initial bolus 20 mg, followed by boluses of 20–80 mg or an 
infusion starting at 1–2 mg/min and titrated up to until the 
desired hypotensive effect is achieved is particularly effective. 
Bolus injections of 1 to 2 mg/kg have been reported to produce 
precipitous falls in BP and should therefore be avoided; maximum 
cumulative dose of 300 mg over 24 h
Nicardipine Acute myocardial ischemiac
Acute renal failure/microangiopathic anemia
Acute ischemic stroke/intracerebral bleed Eclampsia/
preeclampsia
Hypertensive encephalopathy
Sympathetic crisis/cocaine overdosed
5 mg/h; titrate to effect by increasing 2.5 mg/h every 5 min to 
a maximum of 15 mg/h.
Notes: In combination with nitroglycerin (up to 200 µg/min); In combination with a loop diuretic; May be added if pressure is controlled poorly with labetalol/esmolol 
alone; In combination with a benzodiazepine.Vascular Health and Risk Management 2008:4(3) 620
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bolus doses prior to incrementally increasing the maintenance 
infusion rate complicates the dosing of the drug. Additionally, 
because it is metabolized by RBC esterases, any condition that 
precipitates anemia will prolong its “short half-life”.
Caution needs to be exercised when using esmolol in 
patients with chronic obstructive lung disease as it can pre-
cipitate bronchospasm. In addition, ACC/AHA guidelines 
conclude it may be contraindicated for patients already on 
β-blocker therapy, bradycardic patients, and decompensated 
heart failure patients as its use may compromise myocardial 
function (Hunt et al 2005).
Labetalol
Labetalol is a combined selective α1-adrenergic receptor 
blocker and nonselective β-adrenergic blocker given by 
IV bolus or continuous infusion. When given IV, the α- to 
β-blocking ratio of is 7:1 (Lund-Johansen 1984). Labetalol 
is metabolized by the liver to form an inactive glucuronide 
conjugate (Kanto et al 1981). This agent has been used in 
the setting of pregnancy-induced hypertensive crisis because 
little placental transfer occurs mainly due to the negligible 
lipid solubility of the drug (Pearce and Wallin 1994).
The hypotensive effect of labetalol begins within 2 to 
5 minutes after its IV administration, The onset of action occurs 
within 2 to 5 minutes after its IV administration, reaching a 
peak at 5 to 15 minutes following administration, and lasting 
for about 2 to 4 hours (Kanto et al 1981; Goldberg et al 1990). 
The elimination half-life of labetalol is approximately 5.5 hours 
(Bedford Laboratories 2000). This variability makes labetalol 
extremely difﬁ  cult to titrate as a continuous infusion.
Labetalol may be administered at a loading dose of 20 mg, 
followed by incremental doses of 20 to 80 mg at repeated 
10-minute intervals until the desired BP is achieved. Alterna-
tively, after the initial loading dose, an infusion commencing 
at 1 to 2 mg/min and titrated up to until the desired hypotensive 
effect is achieved is particularly effective. Bolus injections of 
1 to 2 mg/kg have been reported to produce precipitous falls 
in BP and should therefore be avoided (Rosei et al 1975).
Labetalol reduces the systemic vascular resistance without 
reducing total peripheral blood ﬂ  ow. In addition, the cerebral, 
renal, and coronary blood ﬂ  ows are maintained (Marx and 
Reid 1979; Wallin 1985; Pearce and Wallin 1994; Olsen et al 
1995). Due to its β-blocking effects, the heart rate is either 
maintained or slightly reduced. Unlike pure β-adrenergic 
blocking agents that decrease cardiac output, labetalol main-
tains cardiac output (Pearce and Wallin 1994).
However, the use of labetalol following cardiac surgery 
has produced mixed results (Meretoja et al 1980; Morel et al 
1982; Cruise et al 1989). Some studies (Meretoja et al 1980; 
Cruise et al 1989) noted a signiﬁ  cant reduction in heart rate 
and blood pressure along with reductions in cardiac index. 
These differences in results may be attributable to the doses 
used and the study population differences, particularly 
regarding left ventricular function. Labetalol should be used 
with caution in patients with heart failure and avoided in 
patients with severe sinus bradycardia, heart block greater 
than ﬁ  rst degree, and asthma.
Clevidipine
Clevidipine, a third generation dihydropyridine calcium 
channel blocker (CCB) developed for use in situations where 
stringent BP control is vital, is an ultrashort-acting selective 
arteriolar vasodilator (Ericsson et al 1999a; Bailey et al 2002; 
Rodríguez and Varon 2006). Clevidipine has a mean blood 
ﬂ  ow clearance of 0.105 L/kg/min and a volume of distribu-
tion of 0.51 L/kg. The half-life is approximately 2 minutes 
(Garcia and Vidt 1987).
Clevidipine acts by selectively inhibiting the inﬂ  ux of 
extracellular calcium through the L-type channel, relaxing 
smooth muscle of small arteries, and reducing peripheral vas-
cular resistance (Ericsson et al 1999b). Clevidipine is rapidly 
metabolized by RBC esterases; therefore its metabolism is 
not affected by renal or hepatic function. Clevidipine reduces 
BP by a direct selective effect on arterioles, thereby reducing 
afterload without affecting cardiac ﬁ  lling pressures or causing 
reﬂ  ex tachycardia (Nordlander et al 1996). Stroke volume 
and cardiac output usually increase. In addition to maintain-
ing renal function and splanchnic blood ﬂ  ow, clevidipine has 
been shown to protect against ischemia/reperfusion injury in 
an animal model of myocardial ischemia (Segawa et al 2000, 
2002; Stephens and Jandhyala 2002).
Several trials have shown clevidipine to be very effective 
in the control of preoperative and postoperative hypertension 
(Kieler-Jensen et al 2000; Powroznyk et al 2003). In a recent 
randomized, double-blind, placebo-controlled multicenter 
trial of 152 patients scheduled for cardiac surgery with current 
or recent hypertension were randomized to receive clevi-
dipine or placebo preoperatively (Levy et al 2007). Patients 
received infusions of either clevidipine (0.4–8.0 µg·kg−1·min−1) 
or placebo (20% lipid emulsion) for at least 30 minutes. 
Patients treated with clevidipine demonstrated a signiﬁ  cantly 
higher rate of treatment success as compared to placebo 
treated group (92.5% vs 17.3% respectively, P  0.0001), 
and a signiﬁ  cantly lower treatment failure rate than patients 
receiving placebo (7.5% vs 82.7% respectively, P  0.0001). 
Clevidipine achieved target blood pressures (systolic blood Vascular Health and Risk Management 2008:4(3) 621
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pressure reduced by 15%) at a median of 6.0 minutes. 
Adverse events for each treatment group were similar.
While the role of this drug in hypertensive emergencies 
is yet to be determined, its proﬁ  le makes it a potentially ideal 
drug for this indication. Clevidipine is not yet available for use 
in the United States beyond clinical trials. In the author’s own 
experience, the use of clevidipine in acute hypertension in the 
emergency department setting is safe and provides a predict-
able blood pressure control. In addition, this drug is safe when 
infused for as long as 96 hours (Varon et al 2007).
Nicardipine
Nicardipine is a short-acting dihydropyridine calcium chan-
nel blocker (CCB) available for both IV and oral use. Likely 
due to its augmentation of coronary blood ﬂ  ow and ability to 
produce potent, more selective vasodilation in the coronary 
circulation than in the systemic vascular bed, IV nicardipine 
has been shown to reduce both cardiac and cerebral ischemia 
(Schillinger 1987); (Kaplan 1990).
The nicardipine dosage is independent of the patient’s 
weight, with an initial infusion rate of 5 mg/h, increasing by 
2.5 mg/h every 5 minutes to a maximum of 15 mg/h until the 
desired BP reduction is achieved (Varon and Marik 2000). In 
the author’s experiences much higher doses are commonly used 
(30–45 mg/hr). The onset of action of IV nicardipine is from 5 
to 15 minutes, with duration of action of 4 to 6 hours.
A therapeutic beneﬁ  t of nicardipine is that the agent has 
been demonstrated to increase both stroke volume and coro-
nary blood ﬂ  ow with a favorable effect on myocardial oxygen 
balance (Lambert et al 1985, 1986, 1987; Schillinger 1987; 
Vincent et al 1997). This property is beneﬁ  cial in patients with 
coronary artery disease and systolic heart failure. In addition, 
this agent has been recommended in the American Heart 
Association/American Stroke Association’s guidelines for the 
treatment of ischemic stroke when diastolic blood pressure is 
120 mm Hg or the systolic blood pressure is 220 mm Hg 
(Adams et al 2003, 2005; Broderick et al 2007).
Fenoldopam
Fenoldopam is a peripheral dopamine-1 (DA) receptor ago-
nist administered by IV infusion for the treatment of severe 
hypertension. Fenoldopam is unique among the parenteral 
BP agents because it mediates peripheral vasodilation by 
acting on peripheral dopamine-1 receptors. Fenoldopam is 
rapidly and extensively metabolized by conjugation in the 
liver, without participation of cytochrome P-450 enzymes. 
Fenoldopam has been associated with an increase in urine 
output and occasionally an increase in creatinine clearance 
(White and Halley 1989; Elliott et al 1990; Shusterman et al 
1993) which makes fenoldopam use appealing in periopera-
tive patients with or at risk for renal dysfunction.
The onset of action of fenoldopam is within 5 minutes, 
with the maximal response being achieved by 15 minutes 
(Weber et al 1988; White et al 1988; Munger et al 1990; 
Bodmann et al 1993). The elimination half-life of fenoldopam 
is ~5 minutes (Bedford Laboratories 2004), with a duration 
of action from 30 to 60 minutes. Blood pressure gradually 
returns to pretreatment values without rebound once the 
infusion is stopped (White et al 1988; Munger et al 1990; 
Bodmann et al 1993).
An initial starting dose of 0.1 µg/kg/min is recom-
mended for fenoldopam, titrated by increments of 0.05 to 
0.1 µg/kg/min to a maximum of 1.6 µg/kg/min.
While fenoldopam provides rapid blood pressure reduc-
tion, this change is often accompanied by reﬂ  ex tachycardia 
(Bednarczyk et al 1989; Elliott et al 1990). Therefore, as with 
sodium nitroprusside, fenoldopam should be used with cau-
tion in patients at risk for myocardial ischemia. Additionally, 
fenoldopam causes dose-dependent increases in intraocular 
pressure, and its use should be avoided in patients at risk with 
intraocular hypertension and intracranial hypertension. In 
addition, fenoldopam is contained in a solution that contains 
a sodium metabisulfate, and patients with potential sulﬁ  te 
sensitivity may develop acute allergic reactions.
Hydralazine
Hydralazine is a direct-acting arteriolar vasodilator, often 
chosen as a ﬁ  rst-line agent for critically ill patients with 
pregnancy-induced hypertension that produces a rapid blood 
pressure reduction, affecting diastolic more than systolic 
blood pressure.
The onset of action after either IM or IV administration 
is approximately 5 to 15 minutes followed by a progressive 
and often precipitous fall in BP that can last up to 12 hours 
(Schroeder 1951; Shepherd et al 1980), however; its maximum 
effect is usually noted between 10–80 minutes. Some anesthe-
siologists have found that 2 to 3 mg boluses can allow for a 
more controlled reduction in blood pressure in the periopera-
tive setting (Tietjen et al 1996).
Although the circulating half-life of hydralazine is only 
approximately 3 hours, the half-time of its effect on BP is 
approximately 10 hours (O’Malley et al 1975; Ludden et al 
1980). Duration is dependent on hepatic acetylation and 
inactivation, making it difﬁ  cult to titrate the drug to effect.
Its reduction of peripheral vascular resistance leads to a 
reﬂ  ex tachycardia that can increase cardiac output. Therefore, Vascular Health and Risk Management 2008:4(3) 622
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hydralazine would not be a good choice in a patient with 
ischemic heart disease who may not tolerate the increased 
myocardial oxygen consumption associated with the cardio-
vascular effects (Powers et al 1998).
It should also be avoided in patients suspected of having 
a dissecting aneurysm. Because of the potent vasodilation of 
cerebral vessels caused by hydralazine, increased intracranial 
pressure may occur (James and Bedford 1982). Although the 
clinical importance of this action is controversial, hydralazine 
is best avoided in patients with intracranial processes (eg, 
head injury) in which increased intracranial pressure is an 
issue. In contrast, the increased renal blood ﬂ  ow attributable 
to hydralazine can be considered a potential advantage in 
patients with impaired renal function.
Because of the prolonged and unpredictable antihyper-
tensive effects of hydralazine and the inability to effectively 
titrate its hypotensive effect, it is best avoided in the manage-
ment of hypertensive crises.
Nitroglycerin
Nitroglycerin, an antianginal as well as antihypertensive 
drug, is a direct vasodilator of peripheral capacitance and 
resistance vessels. It is a greater venodilator than it is an 
arterial dilator. Nitroglycerin is more potent as a venodilator 
than it is an arterial dilator, but arterial dilation does occur at 
high doses (Bussmann et al 1992). By decreasing preload, 
nitroglycerin decreases left ventricular end diastolic volume 
and pressure, and reduces myocardial oxygen demand. Nitro-
glycerin also dilates coronary arteries, increasing the blood 
supply to ischemic regions of the heart.
Nitroglycerin reduces BP by reducing preload and cardiac 
output; undesirable effects in patients with compromised 
cerebral and renal perfusion. Intravenous nitroglycerin 
has an onset time of 2–5 minutes, duration of action of 
~10–20 minutes, and is eliminated by hepatic metabolism 
in ~1–4 minutes (Gerber and Nies 1990; Straka et al 1996) 
(Parke Davis Pharmaceuticals Ltd. 2000). It has pharmaco-
kinetic properties similar to sodium nitroprusside. Hypoten-
sion and reﬂ  ex tachycardia are common occurrences with 
nitroglycerin therapy, which are exacerbated by the volume 
depletion characteristic of hypertensive emergencies.
Nitroglycerin is not to be considered an acceptable pri-
mary therapy in the management of either hypertensive emer-
gencies or urgencies (Varon and Marik, 2003), but may be a 
suitable adjunct therapy as it may have little or no efﬁ  cacy 
when used alone and its antihypertensive action is caused 
by venodilation. Low-dose administration (approximately 
60 mg/min) may, however, be used as an adjunct to IV 
antihypertensive therapy in patients with hypertensive 
emergencies associated with acute coronary syndromes or 
acute pulmonary edema.
Sodium nitroprusside
Sodium nitroprusside is an arterial and venous vasodilator 
that decreases both afterload and preload (Robin and 
McCauley 1992; Friederich and Butterworth 1995). This 
results in a decrease in peripheral resistance without causing 
an increase in venous return.
Sodium nitroprusside is often considered a drug of choice 
for hypertensive emergencies, since it has an immediate onset 
of action and duration of effect of only 2 minutes. In patients 
with adequate circulating blood volume, nitroprusside has 
a predictable dose-response relationship, making it easy to 
titrate, and its efﬁ  cacy has been widely documented in the 
perioperative setting (Kaplan and Jones 1979; Domenighetti 
and Perret 1982; van Wezel et al 1989; Halpern et al 1992; 
Leslie et al 1994).
Nitroprusside is a very potent agent, with an onset of 
action of seconds, a duration of action of 1 to 2 minutes, 
and a plasma half-life of 3 to 4 minutes (Friederich and 
Butterworth 1995). Due to its potency, rapidity of action, 
and the development of tachyphylaxis, the authors recom-
mend intraarterial BP monitoring. In addition, sodium 
nitroprusside requires special handling to prevent its 
degradation by light. These factors limit the use of this drug 
(Tumlin et al 2000).
Nitroprusside decreases cerebral blood ﬂ  ow while 
increasing intracranial pressure (ICP), effects that are 
particularly detrimental in patients with hypertensive 
encephalopathy or following a cerebrovascular accident 
(Anile et al 1981; Griswold et al 1981; Kondo et al 1984; 
Hartmann et al 1989). In unanesthetized patient’s sodium 
nitroprusside can increase ICP, causing cerebral perfu-
sion pressure to drop (Turner et al 1977; Henriksen and 
Paulson 1982; Murphy and Sage 1988). These elevations 
in ICP may therefore be associated with cerebral ischemia 
despite the beneﬁ  ts of lower blood pressure. In patients 
with coronary artery disease, a signiﬁ  cant reduction in 
coronary perfusion pressure (coronary steal) can occur 
(Mann et al 1978). In addition, the drug’s vasodilatory 
adverse effects are frequently not predictable or prevent-
able, and may involve organs other than the heart (eg, 
pulmonary shunting).
Another disadvantage of sodium nitroprusside involves 
accumulation of cyanide and thiocyanate. Sodium nitro-
prusside is nonenzymatically converted to cyanide, which Vascular Health and Risk Management 2008:4(3) 623
Perioperative hypertension
is converted by the liver to thiocyanate which is 100 times 
less toxic than cyanide (Pasch et al 1983; Hall and Guest 
1992). Thiocyanate is mainly eliminated through the kidneys. 
Cyanide removal therefore requires adequate liver function, 
renal function, and bioavailability of thiosulfate. Thus, nitro-
prusside may cause cytotoxicity due to the release of cyanide, 
with interference of cellular respiration (Izumi et al 1993; 
Niknahad and O’Brien 1996). In the authors’ experience, 
patients can develop cyanide toxicity as early as 6–8 hours 
after initiation of the infusion.
Cyanide will also interfere with the vasodilator activity of 
sodium nitroprusside and lead to tachyphylaxis. This occur-
rence is more prevalent with high infusion rates (3 µg/kg/min) 
and prolonged administration (72 hours). Patients receiving 
high infusion rates for an extended duration may require 
periodic thiocyanate monitoring.
Data suggest that nitroprusside infusion rates 4 µg/kg/min, 
for as little as 2 to 3 hours may lead to cyanide levels in the 
toxic range (Pasch et al 1983). Unfortunately, the develop-
ment of toxicity cannot be predicted and may occur with 
lower doses (Cetnarowski and Conti 1986; Murphy and 
Sage 1988; Robin and McCauley 1992). Moreover, the 
recommended doses of nitroprusside of up to 10 µg/kg/min 
results in cyanide formation at a far greater rate than human 
beings can detoxify. Sodium nitroprusside has also been 
demonstrated to cause cytotoxicity through the release of 
nitric oxide, with hydroxyl radical and peroxynitrite genera-
tion leading to lipid peroxidation (Niknahad and O'Brien 
1996; Gobbel et al 1997; Nakamura et al 1997; Rauhala 
et al 1998).
Considering the potential for severe toxicity with 
nitroprusside, this drug should only be used when other 
IV antihypertensive agents are not available and then, only 
in speciﬁ  c clinical circumstances in patients with normal 
renal and hepatic function (Robin and McCauley 1992). An 
initial starting dose of 0.5 µg/kg/min; titrate as tolerated. 
The duration of treatment should be as short as possible, 
and the infusion rate should not be 2 µg/kg/min. An 
infusion of thiosulfate should be used in patients receiving 
higher dosages (4–10 µg/kg/min) of nitroprusside (Hall and 
Guest 1992).
Conclusions
Acute hypertension is common after major surgery and may 
be associated with an increased risk of serious cardiac and 
neurologic, complications. Hypertensive urgencies, and 
emergencies, occur in approximately 50% of patients during 
and immediately after cardiac surgery.
The goal of controlling perioperative hypertension is 
to protect organ function, and is currently recommended 
based on the assumption that the risk of complications will 
be reduced and outcomes improved. However, the treatment 
of acute elevations in BP (deﬁ  ned as an increase in systolic 
BP, diastolic BP, or mean arterial pressure by 20% over 
baseline in the perioperative period) is without a uniform 
approach. While attempts have been made to standardize 
the method to characterize the intraoperative hemodynamics, 
these methods still vary widely. Moreover, there is a lack of 
consensus concerning treatment thresholds and appropriate 
therapeutic targets, making absolute recommendations about 
treatment difﬁ  cult. Nevertheless, perioperative hypertension 
requires careful management.
In general, the treatment goal should be based on the 
patient’s preoperative BP. A conservative target would be 
approximately 10% above that baseline; however, a more 
aggressive approach to lowering BP may be warranted for 
patients at very high risk of bleeding or with severe heart 
failure who would beneﬁ  t from afterload reduction. Careful 
monitoring of patient response to therapy, and adjustment of 
treatment, are paramount to safe and effective treatment of 
perioperative hypertension. After surgery, the clinician can 
safely transition the patient to an effective oral antihyperten-
sive regimen to manage the long-term risks of hypertension 
and cardiovascular diseases.
When considering a potential course of treatment, the 
central question is how to balance the risks associated with 
hypertension versus the risk of end organ hypoperfusion that 
may accompany antihypertensive therapy. When treatment is 
necessary, therapy should be individualized for the patient. 
The choice of agent in speciﬁ  c cases should be determined 
by the clinical situation, the patient’s characteristics, the 
setting of care, and the experience of the clinicians. A wide 
selection of available intravenous antihypertensive agents has 
provided the clinician with the ability to optimize therapy 
based on the speciﬁ  c needs of the situation and condition 
of the patient.
The ideal antihypertensive agent should provide immedi-
ate onset of action, a short to intermediate duration of action, 
be easy to titrate precisely, and have demonstrated safety and 
efﬁ  cacy in the treatment of perioperative hypertension. Newer 
agents such as fenoldopam, nicardipine and clevidipine are 
valuable additions to the arena of effective pharmacological 
options such as enalaprilat, labetalol, nitroglycerin, esmolol, 
and hydralazine. Sodium nitroprusside should only be used 
when other IV antihypertensive agents are not available and 
then, only in speciﬁ  c clinical situations.Vascular Health and Risk Management 2008:4(3) 624
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